Tracking invasive fungal infections after allogeneic hematopoietic stem cell transplant
Retrospective and Prospective Longitudinal Observational Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation
We will follow people who had an allogeneic stem cell transplant to see how often serious fungal infections occur and which clinical factors predict them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Sex | All |
| Sponsor | Peking University People's Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07569055 on ClinicalTrials.gov |
What this trial studies
This is a longitudinal cohort following patients who underwent allogeneic hematopoietic stem cell transplantation at Peking University People's Hospital and collaborating centers since January 1, 2014, to document occurrences of invasive fungal disease (IFD). Clinical data, diagnostic results, antifungal prevention and treatment regimens, pathogen types, and outcomes will be collected and analyzed over time. The project aims to describe changing epidemiology, compare pathogen spectra and clinical features, and identify prognostic factors associated with IFD and IFD-related mortality. Findings will be compared with prior multicenter data (such as CAESAR 2.0) to understand trends after changes in prevention and diagnostic practices.
Who should consider this trial
Good fit: Ideal candidates are patients who underwent allogeneic HSCT at Peking University People's Hospital or the listed collaborating centers since January 1, 2014 and who can be followed for outcome data.
Not a fit: Patients who cannot provide reliable follow-up information (for example due to severe mental disorder or loss to follow-up) or who are deemed unsuitable by investigators may not benefit from participation.
Why it matters
Potential benefit: If successful, this work could help doctors identify transplant recipients at highest risk for invasive fungal infections and guide prevention and early treatment to reduce deaths and complications.
How similar studies have performed: Large cohort efforts such as CAESAR 2.0 have documented one-year incidence, high mortality, and shifts in pathogen patterns after allo-HSCT, but predictive models for individual risk remain limited, so this work builds on prior descriptive findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Since January 1, 2014, patients who underwent allo-HSCT at Peking University People's Hospital and other assistance centers. Exclusion Criteria: 1. For any reason, such as the occurrence of severe mental disorders, the follow-up information may be unavailable; 2. Patients deemed unsuitable for the study by the researchers.
Where this trial is running
Beijing, Beijing Municipality
- Peking University People's Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Xiao-Hui Zhang, MD — Peking University Institute of Hematology, Peking University People's Hospital
- Study coordinator: Jin Wu, MD
- Email: wujin1996@126.com
- Phone: 086-01088326002
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.